Butyl Acetate

• May temporariy relieve symptoms associated with household chemicals sensitivities, such as dizziness and headache.** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.ICD-10: R51.9

DIRECTIONS: Adults and children 5 to 10 drops orally, 3 times daily or as otherwise directed by a health care porfessional. If symptoms persist for more than 7 days, consult your health care professional. Consult a physician for use in children under 12 years of age.

If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Do not use if tamper evident seal is broken or missing. Store in a cool, dry place.

Recent PubMed references pinned to Butyl Acetate as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• [Determination of isopropyl acetate, tert-butyl acetate and sec-butyl acetate in workplace air by solvent desorption-gas chromatography].
  Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases · 2026 · Chen GL, Hu JW, Yuan J, et al.
  PMID 42092254DOI 10.3760/cma.j.cn121094-20241111-00518
• Formation of trifluoroacetic acid from common trifluoromethyl pesticides in agricultural soils.
  Journal of environmental quality · 2026 · Johnsen AR, Henriksen T, Albers CN, et al.
  PMID 41814509DOI 10.1002/jeq2.70160
• Immobilization and biochemical characterization of porcine pancreatic lipase on a magnetic metal-organic framework (mZIF-67) and its application in the synthesis of butyl acetate.
  International journal of biological macromolecules · 2026 · Badoei-Dalfard A, Abdolaliyan Z, Karami Z, et al.
  PMID 41330495DOI 10.1016/j.ijbiomac.2025.149326
• Central Composite Design Optimization for the Synthesis of Butyl Acetate Catalyzed by Liquid Lipase.
  Biotechnology and applied biochemistry · 2026 · Jiang MY, Yu ZT, Zhang MT, et al.
  PMID 40916484DOI 10.1002/bab.70050
• A simultaneous detection method for eight iodinated, brominated, and chlorinated haloacetic acid disinfection byproducts in human urine: liquid-liquid extraction-acidified methanol derivatization-gas chromatography.
  Analytical methods : advancing methods and applications · 2025 · Bai X, Liu L, Qian J, et al.
  PMID 39932254DOI 10.1039/d4ay02254h
• Analysis of Pz-1, a promising therapeutic for organophosphorus poisoning from rodent plasma by liquid chromatography-tandem mass spectrometry.
  Journal of pharmaceutical and biomedical analysis · 2025 · Bilkis K, Khalaf MMR, Fink DM, et al.
  PMID 39793368DOI 10.1016/j.jpba.2024.116650
• Construction of a redox-coupled pathway co-metabolizing glucose and acetate for high-yield production of butyl butyrate in Escherichia coli.
  Bioresource technology · 2024 · Zhang T, Liu G, Li Y, et al.
  PMID 39244107DOI 10.1016/j.biortech.2024.131437
• Biofiltration of n-butyl acetate with three packing material mixtures, with and without biochar.
  Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering · 2024 · Halecký M, Mach J, Zápotocký L, et al.
  PMID 38571317DOI 10.1080/10934529.2024.2332127

The 10 most recently updated of 25 ClinicalTrials.gov registrations naming Butyl Acetate as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
  Active not recruiting · Phase 3 · Interventional · 525 enrolled · National Cancer Institute (NCI)
  NCT00644228updated 2026-06-11
• Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
  Recruiting · Phase 3 · Interventional · 510 enrolled · SWOG Cancer Research Network
  NCT05561387updated 2026-06-10
• Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
  Active not recruiting · Phase 3 · Interventional · 847 enrolled · National Cancer Institute (NCI)
  NCT02112916updated 2026-06-03
• Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
  Recruiting · Phase 3 · Interventional · 1,450 enrolled · ECOG-ACRIN Cancer Research Group
  NCT04566328updated 2026-05-15
• Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
  Active not recruiting · Phase 2 · Interventional · 70 enrolled · National Cancer Institute (NCI)
  NCT06169215updated 2026-05-13
• Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
  Active not recruiting · Phase 1 · Phase 2 · Interventional · 10 enrolled · University of Southern California
  NCT05514990updated 2026-05-13
• Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
  Recruiting · Phase 3 · Interventional · 338 enrolled · SWOG Cancer Research Network
  NCT06022939updated 2026-05-06
• S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
  Completed · Phase 1 · Phase 2 · Interventional · 142 enrolled · SWOG Cancer Research Network
  NCT01668719updated 2026-04-28
• Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
  Active not recruiting · Phase 1 · Phase 2 · Interventional · 49 enrolled · Mayo Clinic
  NCT05392946updated 2026-04-21
• Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  Active not recruiting · Phase 2 · Interventional · 40 enrolled · M.D. Anderson Cancer Center
  NCT03763162updated 2026-04-15

Frequently asked questions

What is Butyl Acetate used for?

According to FDA labeling, Butyl Acetate carries indications including: May temporariy relieve symptoms associated with household chemicals sensitivities, such as dizziness and headache.** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.